Similar to ICAM-1, the increased FGG expression was also associated with worse long-term progression-free and overall survival outcomes in NSCLC patients according to Kaplan-Meier estimate (Supplementary Fig. S5A). This evidence concerns the gene ICAM1 and non-small cell lung carcinoma.